Research classification: Compound-specific clinical and pharmacology studies
Compound overview
CJC-1295 is associated with research on growth-hormone-releasing-hormone analogues; ipamorelin is a synthetic growth-hormone secretagogue. They are distinct molecules.
Published research
Human studies evaluated a long-acting CJC-1295 compound and separately characterized the pharmacokinetics and growth-hormone response of ipamorelin. Those papers provide context for two different research programs.
Evidence limitations
The published long-acting CJC-1295 study does not establish results for a non-DAC variant, and research on individual ingredients does not establish outcomes for a combined formulation. Verify the precise variant, sequence, and proportions before citing compound-specific results.
Primary publications and technical references
- CJC-1295 human pharmacology study (2006) — view source
- Ipamorelin human PK/PD study (1999) — view source
Literature summaries are educational and refer only to the specific preparations and methods studied by the cited authors. These publications do not demonstrate that any APEP Biolabs material is suitable for human or veterinary use. Not medical advice. Laboratory research only. Do not administer or consume research materials.